# Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies

> **NCT00629200** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 33 (actual)

## Conditions studied

- Advanced Cancer
- Solid Tumors

## Interventions

- **DRUG:** Sodium Stibogluconate
- **DRUG:** Interferon Alpha-2b

## Key facts

- **NCT ID:** NCT00629200
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09-13
- **Primary completion:** 2010-02-10
- **Final completion:** 2010-02-10
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2018-11-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00629200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00629200, "Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00629200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*